You are here: HomeNews2021 04 17Article 431914

General News of Saturday, 17 April 2021

Source: www.mynigeria.com

Coronavirus vaccine: Nigeria records 8,439 side effects - NPHCDA

Executive Director of the National Primary Health Care Development Agency, Faisal Shuaib Executive Director of the National Primary Health Care Development Agency, Faisal Shuaib

The National Primary Health Care Development Agency has indicated that a total of 8,439 mild Adverse Events Following Immunisation have been recorded across Nigeria since the covid-19 vaccination began on March 15, 2021.

The Executive Director of the National Primary Health Care Development Agency, Faisal Shuaib on Friday, April 16, 2021, made this announcement at a joint press conference.

The meet the press was organised by the NPHCDA and the World Health Organisation to update Nigerians on the ongoing covid-19 vaccination exercise.

According to Mr Shuaib, five states have the highest records of the AEFI namely: Kaduna (970) Cross River (859), Yobe (541), Kebbi (511), and Lagos (448).

He noted that the country is yet to record any death or case of blood clots related to the administration of the vaccine.

“In Nigeria, since the vaccination programme was officially rolled out on April 15, 2021, a total of 8,439 mild Adverse Events Following Immunisation have been reported.

“These range from pain, swelling at the site of the inoculation, to body pains and nausea. Similarly, 52 cases of moderate to severe incidents of AEFI have been reported.

“These presented as fever, vomiting, diarrhea headaches, dizziness, and allergic reactions. Five states have the highest records of the AEFI namely: Kaduna (970) Cross River (859), Yobe (541), Kebbi (511), and Lagos (448).

“There has been no death from the administration of the vaccine. We have also not diagnosed any case of blood clots related to the administration of the vaccines.

“Nevertheless, we are working with NAFDAC, NCDC, and other relevant agencies to set up a more active surveillance system built on our experience with polio surveillance,” he said.